Price movement over the last 24 hours
Adaptive Biotechnologies Corp vs Hyatt Hotels Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Hyatt Hotels Corporation trades at $187.35 (market cap $18.19B). The key difference: Hyatt Hotels Corporation is far larger — about 5.5× Adaptive Biotechnologies Corp's market cap, and Hyatt Hotels Corporation pays a 0.31% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | H | |
|---|---|---|
Market Cap | $3.33B | $18.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $202.09 |
52-Week Low | $10.24 | $135.01 |
Enterprise Value | $3.19B | $22.03B |
Dividend Yield | — | 0.31% |
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →